Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty


Contact us for more batch information
Select Batch
Resource Download


Catalog No. T0407Cas No. 89-25-8
Edaravone (MCI-186)(MCI-186) is a potent new free radical scavenger used for the therapy of patients with acute brain infarction.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePrice/USDAvailabilityQuantity
500 mg$43In Stock
5 g$52In Stock
1 mL x 10 mM (in DMSO)$48In Stock
Bulk & Custom
Add to Cart
View More

Related Compound Libraries of "Edaravone"

Product Introduction

Edaravone (MCI-186)(MCI-186) is a potent new free radical scavenger used for the therapy of patients with acute brain infarction.
In vitro
Edaravone significantly improves neurological function in animals. Treatment with edaravone substantially reduces TUNEL-positive apoptotic cells and increases the expression of Bcl-2, while decreasing the immunoreactivity of Bax protein in the peri-infarct area. The research demonstrates that edaravone provides excellent protection against ischemic/reperfusion-induced brain injury through a Bcl-2/Bax protein-dependent anti-apoptotic mechanism. Following a 24-hour infusion of edaravone into murine brain tissue, there is a notable reduction in infarct volume and amelioration of neurological deficits. In the early stages post-reperfusion, edaravone significantly inhibits the accumulation of HNE-modified proteins and 8-OHdG in the penumbral region, reduces the expression of iNOS, diminishes microglial activation, and lowers the formation of nitrotyrosine. Edaravone also markedly attenuates renal function and pathological outcomes in rat kidneys, significantly reducing free radical production in renal tubular epithelial cells as indicated by fluorescence.
In vivo
Edaravone optimizes the state of NOS by reducing the detrimental isoforms iNOS and nNOS, while increasing the beneficial eNOS, thus favoring neuroprotection in ischemic stroke. It inhibits oxidation and enhances eNOS expression without boosting production, improving and preserving cerebral blood flow during reperfusion without necessitating peroxynitrite formation. Edaravone exerts its neuroprotective effect by mitigating neuronal damage from cerebral ischemia and inhibiting endothelial injury.
Cell Research
Cell viability is quantified by MTT assay and trypan blue staining. MTT (5?mg/mL, 20?μL) is added to each well and incubated for 4?h at 37°C after the drug treatments. The medium is removed and the cell pellet is dissolved in DMSO. Then, the optical density (OD) values are measured at 570?nm using an ELISA reader.
Chemical Properties
Molecular Weight174.2
Cas No.89-25-8
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 45 mg/mL (258.32 mM)
Solution Preparation Table
1 mM5.7405 mL28.7026 mL57.4053 mL287.0264 mL
5 mM1.1481 mL5.7405 mL11.4811 mL57.4053 mL
10 mM0.5741 mL2.8703 mL5.7405 mL28.7026 mL
20 mM0.2870 mL1.4351 mL2.8703 mL14.3513 mL
50 mM0.1148 mL0.5741 mL1.1481 mL5.7405 mL
100 mM0.0574 mL0.2870 mL0.5741 mL2.8703 mL


  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg,each TargetMol | Animal experiments animal weighs 20 g, and the dosage volume is 100 μL. A total of TargetMol | Animal experiments 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL.
Mother liquor preparation method: 2 mg of drug dissolved in 50 μLDMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μLDMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μLTween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify.
1 Enter information below:
2 Enter the in vivo formulation:
%Tween 80

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.